AlloNK, an off-the-shelf experimental natural killer (NK) cell therapy being developed by Artiva Biotherapeutics, soon will enter clinical testing, in combination with rituximab, for systemic lupus erythematosus (SLE) patients with active lupus nephritis. This follows the approval of the company’s investigational new drug application by the U.S.
Immpact Bio has been cleared in the U.S. to start testing its cell therapy IMPT-514 in people with active systemic lupus erythematosus (SLE) that is refractory, or resistant to treatment. The clearance by the U.S. Food and Drug Administration “marks a pivotal milestone for our autoimmune disease clinical…
PALIZADE, a Phase 2b clinical trial of Kezar Life Sciences’ investigational therapy zetomipzomib, is still enrolling systemic lupus erythematosus (SLE) patients with active lupus nephritis, a severe lupus complication that causes kidney damage. The launch of the placebo-controlled PALIZADE trial (NCT05781750) earlier this year followed the completion…
Racial discrimination was found to be associated with increased inflammation among Black women with systemic lupus erythematosus (SLE) in a recent study. Each experience of racial discrimination was tied to a nearly 4% increase in the levels of C-reactive protein (CRP), an inflammation marker, in the bloodstream, the findings…
Disparities in lupus care and outcomes in the U.S. are influenced by structural and social determinants such as race, ethnicity, socioeconomics, education, and healthcare access. These are the findings of a study by the Lupus Foundation of America (LFA) through its Addressing health Inequities in Minorities (AIM)…
The Lupus Foundation of America has announced this year’s winners of the Gina M. Finzi Memorial Student Summer Fellowship Program, designed to support students working in lupus research. Each award, worth $4,000, includes mentorship by an experienced researcher in the field of lupus. Winners, all young scientists, are pursuing…
The Lupus Research Alliance (LRA) has awarded a $3-million grant to a multidisciplinary research group working to identify drivers of lupus nephritis, a serious complication of lupus characterized by kidney damage, in children with the autoimmune disease. Elena Hsieh, MD, an associate professor at the University of Colorado…
Younger age, greater disease activity, and a history of kidney involvement are significant predictors of severe disease flares among people with systemic lupus erythematosus (SLE), a study in Iran has found. The findings suggest that patients with these risk factors “may need closer monitoring and follow-up” to better manage…
A Phase 2 clinical trial assessing the safety and effectiveness of daxdilimab for systemic lupus erythematosus (SLE) didn’t show a statistically significant difference between the experimental therapy and a placebo regarding the proportion of patients who showed signs of reduced disease activity while lowering their daily corticosteroid dose. The…
Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by patients with lupus nephritis, a kidney complication of lupus. That’s according to the full results from AURORA 2 (NCT03597464), a Phase 3 extension study that evaluated how safe…